Delivering specialty medicines for cancer and chronic immune diseases

R-PHARM US1 was established in 2014 as part of the R-Pharm JSC2 strategy to expand into North and South America.

R-Pharm US is a fully integrated specialty pharmaceutical company focused on the development and commercialization of medicines to treat cancer and chronic immune diseases.

more »

1. R-Pharm US Operating LLC is a wholly owned subsidiary of R-Pharm US LLC

2. R-Pharm JSC is the parent company for R-Pharm US LLC

Product Spotlight:

R-PHARM US Acquires IXEMPRA® (ixabepilone) from Bristol-Myers Squibb and Launches U.S. Commercial Operations

(August 17, 2015) With the acquisition, R-PHARM US has launched its U.S. commercial operations, and it is now responsible for all activities surrounding IXEMPRA's manufacture, distribution, sales, and reimbursement. 

more »

 

To see full US Prescribing Information for IXEMPRA, including Boxed Warning regarding hepatic impairment, click on www.Ixempra.com.

What's New

R-PHARM US Expands its Oncology Asset Portfolio with the Exclusive License and Distribution Rights to episil® in the United States

(April 21, 2016) R-PHARM US has gained the exclusive license and distribution rights to commercialize episil® oral liquid in the U.S. from Camurus AB.  Camurus developed episil® as a ready-to-use therapeutic option to manage and relieve the pain associated with oral lesions, including oral mucositis (OM), which results from cancer therapy and other causes. 

more »

 

To see full US Prescribing Information for episil®, click here.

IXE-00001-01